The Christie charity
Topics:
- CAR-T in haematological malignancies
- Ethics and consent in CAR-T
- T-Cell journey
- Management of CAR-T toxicities
- General Haematology Ward Nurses
- Stem Cell Transplant/Cellular Therapy Nurses
- ICU Nurses
- Specialist Haematology Nurses
- Acute Oncology Nurses
- AHPs working with CAR-T patients
- Junior Doctors
Principles of CAR-T - Friday 11 and Friday 18 November 2022
Day 1 - Friday 11 November 2022
| Time | Title of talk | Speaker | Title | Organisation |
|---|---|---|---|---|
| 09:00 | Registration (day 1) | |||
| 09:30 | Introduction to CAR-T/advanced therapies | Dr Reuban Benjamin | Haematologist and honorary clinical senior lecturer | Kings College |
| 10:05 | T-cell journey: process of T-cell collection and manufacturing | Angela Leather | Lead nurse - transplant and clinical nurse specialist | The Christie NHS Foundation Trust |
| 10:40 | CAR-T therapy in haematological malignancies | Professor Adrian Bloor | Consultant in haematology oncology | The Christie NHS Foundation Trust |
11.25 - coffee break
| Time | Title of talk | Speaker | Title | Organisation |
|---|---|---|---|---|
| 11:40 | Advanced therapies in clinical trials (solid tumours) | Professor Fiona Thistlewaite | Medical oncology consultant and medical director of The Christie clinical research facility, honorary professor of experimental immunotherapy | The University of Manchester |
| 12:25 | Ethics and consent in CAR-T | Dr Anna Castleton | Consultant in haematology oncology | The Christie NHS Foundation Trust |
13.10 - lunch break
| Time | Title of talk | Speaker | Title | Organisation |
|---|---|---|---|---|
| 13:55 | Psychological impact of relapsed disease | Anne Crook | Counsellor in psycho-oncology | The Christie NHS Foundation Trust |
| 14:40 | Nursing issues in lymphodepletion and cell infusion | Ruth Clout | Senior clinical practice facilitator | The Christie NHS Foundation Trust |
15.10 - coffee break
| Time | Title of talk | Speaker | Title | Organisation |
|---|---|---|---|---|
| 15:20 | Ambulatory care - CAR-T patients (TYA) | Hanna Simpson | Clinical liaison nurse specialist team leader for teenagers and young adults with cancer | The Christie NHS Foundation Trust |
16.05 - summary and close
Day 2 - Friday 18 November 2022
| Time | Title of talk | Speaker | Title | Organisation |
|---|---|---|---|---|
| 09:00 | Registration (day 2) | |||
| 09:30 | Cytokine release and tumor lysis syndrome (TLS) | Dr Ahmed Abdulgawad | Specialist trainee doctor in haematology | The Christie NHS Foundation Trust |
| 10:05 | Role of critical care in managing CAR-T complications | Dr Anthony Wilson | Consultant | Manchester Foundation Trust |
10.40 - coffee break
| Time | Title of talk | Speaker | Title | Organisation |
|---|---|---|---|---|
| 11:25 | Neurological toxicity | Dr Thomas Seddon | Specialist trainee doctor in haematology | The Christie NHS Foundation Trust |
| 11:40 | Overview of toxicities and infective complications | Ruth Clout | Senior clinical practice facilitator | The Christie NHS Foundation Trust |
12.25 - lunch break
| Time | Title of talk | Speaker | Title | Organisation |
|---|---|---|---|---|
| 13:10 | Haemophagocytic lymphohistiocytosis (HLH) | Dr Samar Kulkarni | Consultant in haematology oncology | The Christie NHS Foundation Trust |
| 13:55 | Post 30-day care | Orla Stewart | Lead haematology nurse | King's College Hospital NHS FT |
| 14:40 | Patient experience |
15.10 - summary and close
Miltenyi Biotec is a global provider of products and services that empower biomedical discovery and advance cellular therapy. Their innovative tools support research at every level, from basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyse, and utilise the cell.
Miltenyi Biotec technologies offer solutions for cellular research, cell therapy, and cell manufacturing. Their more than 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, cancer, haematology, and graft engineering. In their commitment to the scientific community, they also offer comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 4,000 employees in 28 countries – all dedicated to helping researchers and clinicians around the world make a greater impact on science and health.
Founded in 2009 as a pioneer in cell therapy research, Kite’s leadership position in the immuno-oncology space was solidified with its research and development agreement with the National Cancer Institute in 2012, and when its commercial manufacturing site opened in El Segundo in 2016. Since Kite's acquisition by biopharma leader Gilead Sciences in October 2017, its combined strength has accelerated the advancement of its pipeline, including the launch of YESCARTA® (axicabtagene ciloleucel) and TECARTUS® (brexucabtagene autoleucel), and has expanded the impact of its strategic partnerships.
As an independent operating company since 2019, Kite prioritises innovative research and development with the full resources, capabilities, and trust of Gilead. As a vital part of Gilead — a founding member of the Foundation for the NIH’s Partnership for Accelerating Cancer Therapies — Kite is devoted to advancing the understanding of cell therapy as a transformational treatment option for cancer. The combined strength of Kite and Gilead allows them to remain innovative, agile, and ambitious in our mission to keep improving the lives of people with all types of cancer.
Sign up to our education events mailing list to be kept up to date with this and future events